Mobile

A 4-week randomized, double-blind, placebo controlled, parallel group, phase II study to assess the efficacy and safety of gefitinib tablets, 250 mg once daily (OD), in adult patients with moderate ch...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-000418-20

A 4-week randomized, double-blind, placebo controlled, parallel group, phase II study to assess the efficacy and safety of gefitinib tablets, 250 mg once daily (OD), in adult patients with moderate chronic obstructive pulmonary disease (COPD)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy of gefitinib tablets, 250 mg once daily (OD) on symptoms, mainly cough and sputum production, in patients with Chronic Obstructive Pulmonary Disease (COPD) compared to placebo during a 4-week treatment period

Critère d'inclusion

  • Moderate Chronic Obstructive Pulmonary Disease (COPD)

Liens